Healthcare
Alvotech(ALVOW)
Live Price
Offline$0.3301
+0.00% today
1Y Change
-85.33%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $1.10B
- Revenue Growth
- +19.7%
- EPS Growth
- +111.5%
- Dividend Yield
- 0.0%
Coverage: 202 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alvotech (ALVOW) is a Healthcare stock with a market cap of $1.10B and listed on NASDAQ. The stock last traded around $0.33 and down 85.3% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +19.7%, EPS growth of +111.5%, a dividend yield of 0.0%. What stands out right now is revenue +19.7%, EPS +111.5%, free cash flow +61.0% with operating margin 13.3% and ROIC 1.3%. Valuation already assumes a fairly strong business story at P/E 35.2 and price/sales 1.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ALVOW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+19.7% vs +7.6% peer median
Operating Margin
Below sector median
+13.3% vs +19.4% peer median
P/E
Near sector median
35.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +19.7% and EPS at +111.5%, with operating margin around 13.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 18, 2026 | +205.6% | +0.0% | +0.0% | +0.0% |
2025 Nov 12, 2025 | +34.7% | -14.3% | -26.8% | -6.6% |
Benchmark Edge
ALVOW vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ALVOW
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ALVOW Max Drawdown
-93.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ALVOW and SPY.
Company Overview
Alvotech
NASDAQ Global Market
Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.
- Leadership
- Lisa Graver
- IPO Date
- Jun 16, 2022
- Employees
- 1.0k
- Street Address
- Saemundargata 15-19
- Mailing
- Luxembourg, 102
- Region
- Luxembourg, IS
- Reporting Currency
- USD
- Investor Line
- 354 422 4500
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 35.2
- EV/EBITDA
- 30.4
- Price/Sales
- 1.9
- Price/Book
- โ
Growth
- Revenue
- +19.7%
- EPS
- +111.5%
- Free Cash Flow
- +61.0%
Profitability
- Gross Margin
- 59.8%
- Operating Margin
- 13.3%
- Net Margin
- 4.8%
- ROE
- -11.9%
- ROIC
- 1.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.89
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.